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Epidemiology of  Eales Disease in the Central Western India
                                       Review Article
Shah MA*, Shah SM, Kalyani PJ,  Shah AH, Shah PD, Pandya JS
Drashti Netralaya, Dahod, Gujarat, India.
Introduction 
Eales’ disease was first described by Henry Eales, a British oph-
thalmologist, in 1880 and 1882. [1,2] He identified this disease in 
seven male patients ranging in age from 14 to 29 years with recur-
rent retinal hemorrhages. In addition, these patients had histories 
of  headache, variation in peripheral circulation, chronic constipa-
tion, and epistaxis. [2]
Eales’ believed that these symptoms were caused by vasomotor 
neurosis with constriction of  the alimentary vessels and compen-
satory dilatation of  the retinal and nasal vessels. Eales’ did not 
describe retinal vasculitis. [2] However, 5 years later, Wadsworth 
(1887) described signs of  retinal vasculitis. [3] Eales’ has subse-
quently been honored with the eponym for idiopathic retinal Pe-
riphlebitis. [4]
Eales’ disease is an idiopathic inflammatory vasoproliferative dis-
order of  the retinal veins, which leads to the occlusion of  these 
vessels. [5] It affects primarily healthy young adults between the 
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ages of  20 and 40 years. It affects primarily males, (80-90%), but 
can affect females. Elder et al. (1971) reported the possibility of  
bilateral involvement in 90% of  cases. [6] It may rarely affect the 
arterioles. This vascular occlusion, induced by the inflammation 
of  veins, can lead to proliferative vascular retinopathy and subse-
quent sequelae, such as recurrent vitreous hemorrhage, and trac-
tional or combined retinal detachment. [5,7]
Eales’ disease was common a century ago, but its incidence has 
declined in western countries. However, Eales’ disease is wide-
spread in the Indian subcontinent and certain areas of  the Mid-
dle East. It is usually seen unilaterally, but can present bilaterally. 
Eales’ disease is characterized by three overlapping stages of  ve-
nous inflammation (vasculitis), occlusion, and retinal neovascu-
larization. Diagnosis is mostly clinical and requires exclusion of  
other systemic or ocular conditions that could present with simi-
lar retinal features. Recurrent vitreous hemorrhage is the hallmark 
of  Eales’ disease. [7]
Treatment options include systemic steroids during the inflam-
matory stage, retinal photocoagulation usually in the proliferative 
stage to the non-perfused retina, and early vitrectomy for recur-
rent vitreous hemorrhage. [6,7,11] Oral steroids are the primary 
agents used most frequently for the management of  Eales’ dis-
ease, but prolonged systemic use of  steroids is associated with 
serious ocular and systemic side effects. [11] Photocoagulation is 
the mainstay of  treatment in the proliferative stage of  Eales’ dis-
ease. [12] Intravitreal steroids and anti-VEGF have been used in 
many posterior segment ocular pathologies. [13,14] Visual prog-
nosis is good if  treated early in the course of  the disease. [7,12,13] 
Recently, anti-metabolite therapies, especially methotrexate, have 
been used in Eales’ disease with some success. [12]
The prognosis of  patients with Eales’ disease is variable and de-
pends on the availability of  medical care. Many of  the patients in 
the region in which this study was conducted live in areas that are 
underserved by medical care. Therefore, the treatment outcome 
may also vary. This study assessed the demographics, clinical pres-
entation and treatment outcome of  Eales’ disease in Central West 
India, which is inhabited by mainly tribal populations.
Methods
This study was a prospective interventional case series, designed 
to evaluate the epidemiology of  Eales’ disease patients in a region 
of  Central Western India; data were collected from January 2004 
to December 2012. The study was conducted in a tertiary care 
teaching hospital and a tribal center for ophthalmic care, which 
serves the second largest tribal belt in India. It is located at the 
junction of  three states, Gujarat, Rajasthan and Madhya Pradesh.
Approval from the Institutional Ethics Committee was obtained 
and all efforts were made to adhere to the guidelines of  the Dec-
laration of  Helsinki.
Patients were briefed about the procedures of  the study and con-
sent was obtained before enrolment.
Patients suspected to have Eales’ disease aged between 20 and 
40 years underwent exhaustive ocular and medical evaluation for 
confirmation of  a diagnosis of  Eales’ disease. Our cohort com-
prised patients diagnosed with Eales’ disease with no other sys-
temic or ocular disease.
Subjects with a history of  diabetes mellitus, hypertension, colla-
gen vascular disease, sarcoidosis, Bechet’s disease, systemic lupus 
erythematosus, Coats’ disease, or syphilis were excluded from the 
study.
Ophthalmic examinations included best-corrected visual acuity 
using Snellen’s chart, intraocular pressure measurement by appla-
nation tonometry, and anterior segment evaluation by slit-lamp 
examination.
Evaluations of  the posterior segment at the initial and each sub-
sequent visit were performed by direct and indirect ophthalmos-
copy, slit-lamp biomicroscopy with 90-D and three-mirror lenses, 
and fundus fluorescein angiography.
Investigations included complete blood count with sickle-cell 
screening, erythrocyte sedimentation count, liver function test, 
fasting plasma sugar level, blood coagulation profiles, Mantoux 
test using 2 TU/0.1 mL purified protein derivative (PPD), and 
chest X-ray.
Ultrasonography was performed to detect fractional retinal de-
tachment in eyes affected by vitreous hemorrhage with no fun-
dus view. The location and extent of  retinal involvement due 
to Eales’ disease, neovascularization, and fibrovascular traction 
were documented in all patients by fundus drawing and digital 
fundus color photography. Optical coherence tomography (OCT) 
was performed using high-density OCT (Cirrus, 2000, Carl Zeiss 
Meditec, CA,) as required after it has became available.
The inflammatory stage was treated with medical management, 
periocular steroids, systemic steroids or methotrexate. Complete 
blood counts and liver function tests were performed at least once 
per month in patients prescribed methotrexate. Prior to prescrib-
ing methotrexate, a thorough medical consultation was performed 
by a medical oncologist. The ischemic stage was treated with anti-
VEGF or photocoagulation according to availability. The stage of  
complications was treated with surgical management. The details 
were documented in a pre-tested, online Eales’ disease form and 
then exported to a Microsoft Excel™ spreadsheet.
Data were analyzed using the SPSS software (ver. 17.0; IBM SPSS 
Inc., Chicago, IL, USA). Univariate parametrical analyses were 
used. A p-value of  < 0.05 was considered to indicate statistical 
significance.
Results
The cohort comprised 74 male patients with a mean ages of  30 
± 8.73 years (Table 1). Demographic factors including age, diet, 
smoking, religion and race were evaluated (Table 2). No signifi-
cant differences in the demographic factors were observed, with 
the exception of  age of  presentation (p = 0.02).
Within the cohort, the presenting visual acuity was < 3/60 in 
64.9% of  eyes. The final visual outcome was > 6/12 in 40 eyes 
(54.1%), 6/60 to 6/18 in 14 eyes (18.9%) and < 1/60 in 9 eyes at 
a mean follow-up of  592 days.
We found the anterior segment normal in 65 (87.8%) cases (Table 
3). We then evaluated the findings in the posterior segment (Ta-
ble 4). The treatments prescribed were systemic steroids (64.9%), 
anti-metabolites (35.1%), photocoagulation (13%), pars plana vit-
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rectomy (32.1%) and revision vitrectomy (9.5%) (Table 4).
We evaluated visual parameters pre- and post-treatment, and 
found a significant difference (p = 0.000, Table 5). We next com-
pared visual outcome following surgical management, and again 
found a significant difference (p = 0.000, Table 6).
Discussion
Our cohort comprised 74 cases with a mean age of  30 ± 8.73 
years. Other reports with a similar demographic profile, including 
age and gender reported similar findings. [7,15-17] In this study, 
we have simplified the classification according to the clinical find-
ings. In the inflammatory stage (stage 1), patients with vitritis and 
vasculitis were treated with systemic and periocular steroids. In the 
ischemic stage (stage 2), patients with neovascularization and is-
chemia were treated with laser or anti-VEGF therapy. During the 
stage of  complications (stage 3), cases of  traction or mixed retinal 
detachment were treated with pars plana vitrectomy. Saxena et al. 
reported a classification and grading system, the proposed clas-
sification system may provide guidelines for the management of  
Eales’ diseases. [15] Periphlebitis and vitreous hemorrhage have 
been reported, but the incidences of  vitritis, vasculitis and vitre-
ous hemorrhage have not been described. [7,15-17]
We observed total posterior vitreous detachment in 24.3% of  
cases. Badrinath et al. reported multifocal vitreo retinal adhesions 
in 87.8% of  cases. [18,19] There was no difference in the response 
to treatment in the Mantoux-positive and -negative groups. [20]
Oral corticosteroids and deep sub-tenon triamcinolone, used for 
quadrants two and three reported by Biswas et al., has a significant 
effect on visual outcome. [21,22] We used anti-metabolites in the 
form of  methotrexate in 35.1% of  cases .[7,22] As suggested by 
many investigators we did not use anti-tubercular therapy for the 
treatment of  Eales’ disease.[7] We used laser photocoagulation in 
the ischemic stage (stage 2) or in those with neovascularization, as 
reported by Biswas et al. [7,23,24]
In the current study, vitrectomy was performed in 32.1% of  cases, 
which is in contrast to the 6–18% reported by Badrinath et al. [19] 
This may be due to the greater number of  patients being in the 
stage of  complications (stage 3) in our study.
Table. 1 Age Category
AGE CATEGORY NUMBER  (N) PERCENT (%)
11 TO 20 4 5.4
21 TO 30 42 56.8
31 TO 40 15 20.3
41 TO 50 11 14.9
51 TO 60 2 2.7
Total 74 100.0
Table. 2 Demographic Results
NUMBER(N) PERCENT(%)
Hindu Tribal 65 87.8
Socio Economic Status Poor 65 87.8
Maize Eater 66 89.2
Smokers 32 43.2
Bilateral 64 86.5
No Systemic Disorder 72 97.3
Follow Up In Days 592 +/- 374.4
Table. 3 Clinical Features in Anterior Segment
FINDINGS NUMBER(N) PERCENT(%)
Cataract 2 2.7
 Chemosis 2 2.7
 Chemosis, Rubeosis Iridis 1 1.4
 Leucokoria 1 1.4
Normal 65 87.8
 Pterygium 2 2.7
 RAPD 1 1.4
 Total 74 100.0
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Table. 4 Clinical Features In Posterior Segment
CLINICAL FINDINGS
PRESENT NO VIEW
NUMBER(N) PERCENT(%) NUMBER(N) PERCENT(%)
Normal  Anterior  Segment 65 87.8
Vitreous Haze 2 Quadrants 20 27 23 31.1
Vitreous Haemorrhage 20 27 23 31.1
Vasculities-St 48 64.9 16 21.6
Vasculities-It 38 51.4 18 24.3
Vasculities-Sn 25 33.8 25 33.8
Vasculities-In 16 21.6 25 33.8
Rubeosis Iridis 6 8.1 10 13.5
NVE/NVD 23 31.1 15 20.3
Macular Edema 24 32.4 17 23
Retinal Detachment 32 43.4
Systemic Steroids 48 64.9
Antimetabolites 26 35.1
Laser 10 13.5
Pars Plana  Vitrectomy 24 32.1
Revision Pars Plana  Vitrectomy 7 9.5
NVD-Neovascularization Disc; NVE-Neovascularization Elsewhere
Table. 5  Comparative Study Of  Vision Following Medical Mamnagment Of  Eales’ Disease
 POST TREATMENT VISION
PRE TREATMENT VISION
Total
<1/60 1/60 TO 3/60 6/60 TO 6/36 6/24 TO 6/18 6/12 TO 6/9
<1/60 14 4 3 0 0 21
1/60 TO 3/60 6 8 0 0 0 14
3/60 TO 5/60 2 0 0 0 0 2
6/60 TO 6/36 5 4 2 1 1 13
6/24 TO 6/18 3 1 1 5 1 11
6/12 TO 6/9 0 1 0 6 1 8
6/6 TO 6/5 0 0 0 0 5 5
Total 30 18 6 12 8 74
P=0.000
Table.6 Comparative Study Of  Vision Following Surgical Management Of  Eales Diseases
 POST OPERATIVE VISION
SURGERY PERFORMED Total
NO PP VIT
<1/60 5 16 21
1/60 TO 3/60 8 5 13
3/60 TO 5/60 2 0 2
6/60 TO 6/36 10 3 13
6/24 TO 6/18 11 0 11
6/12 TO 6/9 7 0 7
6/6 TO 6/5 5 0 5
Total 48 24 72
P=0.000 PP VIT-PARS PLANA VITRECTOMY
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Conclusion
We have studied newer aspects of  demographic details, anterior 
segment findings and posterior segment findings. We have found 
that final visual outcome significantly improved following medical 
or surgical treatment. 
References      
[1]. Eales’ H. (1880) Cases of retinal hemorrhage associated with epistaxis and 
constipation. Birmingham Medical Review 9: 262-3.
[2]. Eales H. (1882) Primary retinal hemorrhage in young men. Ophthalmic 
Rev 1:41.
[3]. Elliot AJ. (1975) 30-year observation of patient with Eales’ disease. Am J 
Ophthalmol 80:404–408.
[4]. Wardsworth. (1887) Recurrent retinal haemorrhage followed by the devel-
opment of blood vessels in the vitreous Ophthalmic Rev 6: 289.
[5]. Das T, Biswas J, Kumar A. (1994) Eales’ disease. Indian J Ophthalmol 
42:3–28.
[6]. Duke-Elder S, Dobree JH. System of Ophthalmology Vol X. London: Hen-
ry Kimpton.
[7]. Biswas J, Sharma T, Gopal L, Madhavan HN, Sulochana KN, et al. (2002) 
Eales’ disease: an update. Surv Ophthalmol 47:197–214.
[8]. Madhavan HN, Therese KL, Gunisha P, Jayanthi U, Biswas J. (2000) Poly-
merase chain reaction for detection of Mycobacterium tuberculosis in epiret-
inal membranes in Eales’ disease. Invest Ophthalmol Vis Sci 41:822–825.
[9]. Biswas J, Rao NA. (1990) Epiretinal membrane in Eales’ disease and other 
vascular retinopathies. Invest Ophllmlmol Vis Sci 31: 369-70.
[10]. Badrinath SS, Biswas J, Sharma T, Rao N. (1992) Immunophenotyping 
of inflammatory infiltrates in epiretinal (ERM) and sub retinal membrane 
(SRM) in Eales’ disease. Invest Ophthalmol Vis Sci 33: 33-35.
[11]. Das T, Namperumalsamy P. (1987) Combined photocoagulation and cryo-
therapy in treatment of Eales’ retinopathy. Proc All Ind Ophthalmol Soc 
45: 108.
[12]. Saxena S, Kumar D. (2000) Safety of oral methotrexate pulsed therapy. In-
dian J Ophthalmol 48:251.
[13]. Pathengay A, Pilli S, Das T. (2005) Intravitreal triamcinolone acetonide in 
Eales’ disease: a case report. Eye 19: 711–713.
[14]. Saxena S, D. Kumar. (2007) New classification system-based visual outcome 
in Eales' disease. Indian J Ophthalmol 55: 267-9.
[15]. Davis J, S. H. Schecter. (2009) Eales' disease: the great masquerader. Op-
tometry 80: 354-9.
[16]. Shrestha J. K, D. Khadka. (2009) Retinal vasculitis. Nepal J Ophthalmol 
1:66-71.
[17]. Stoffelns B. M, C. Kramann. (2009) Eales' disease--10 years experience with 
a rare disease. Klin Monbl Augenheilkd 226: 299-304.
[18]. Badrinath SS, Gopal L, Sharma T. (1999) Vitreoschisis in Eales disease: 
pathogenic role and significance in surgery. Retina: 19:51–4.
[19]. Badrinath SS, Gopal L, Sharma T. (1996) Morphological description Of 
surgical anatomy of Eales disease–A pilot study. Presented at 100th annual 
meeting of American Academy, Chicago.
[20]. Das TP, Namperumalsamy P. (1990) Photocoagulation in Eales disease. Re-
sults of prospective randomized clinical study. Presented at XXVI Int Cong 
Ophthalmol, Singapore. 
[21]. Howe LJ, Stanford MR, Edelsten C, Graham EM. (1994) The efficacy of 
systemic corticosteroids in sight-threatening retinal vasculitis. Eye 8:443–7.
[22]. Greenwood AJ, Stanford MR, Graham EM. (1998) The role of azathiopri-
nein the management of retinal vasculitis. Eye 12:783–8.
[23]. Dayton GO Jr, Straatsma BR. (1962) Eales disease and photocoagulation. 
Trans Pac Coast Ophthalmol Soc 43:12–129.
[24]. Gopal L, Abraham C. (1985) Efficacy of photocoagulation in Eales disease. 
Trans Asia-Pacific Acad Ophthalmol 10:689-90.
